You can help expand this article with text translated from
the corresponding article in Persian. (January 2022) Click [show] for important translation instructions.
|
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Trade names | Spikogen [1] |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
|
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
COVAX-19 (or SpikoGen) is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine, in collaboration with CinnaGen, a private company with operations in the Middle East. It is under clinical trial in collaboration with the Iranian company CinnaGen. [2] [3] [4]
It requires two doses 21 days apart given by intramuscular injection. [3]
COVAX-19 is a recombinant protein subunit. [5]
Vaxine began work on a COVID-19 vaccine in January 2020. After developing a vaccine adjuvant the company decided to focus on a "recombinant protein-based vaccine". A phase 1 human trial started in June 2020. The phase 1 trial involved 40 participants, 30 of whom received the vaccine. The remaining ten participants received a saline placebo. [6]
Phases 2 and 3 clinical trials of COVAX-19 are being conducted in Iran under a co-operation agreement. [7] Phase 2 clinical trials started in May 2021 and Phase 3 trials commenced in August 2021. In the phase 2 trials, 400 Iranian volunteers were injected with either a placebo or the first dose of the vaccine. If the studies are successful, Cinnagen will produce the vaccine under the name SpikoGen in Iran. [6] [8]
Phase | Registration number | Start | Number of participants | Age of participants | Location | Ref | ||
---|---|---|---|---|---|---|---|---|
Total | Vaccine | Placebo | ||||||
I | NCT04453852 | 30 June 2020 | 40 | 30 | 10 | 18–65 years | Adelaide, Australia | [9] [10] |
II | IRCT20150303021315N23 | 30 May 2021 | 400 | 300 | 100 | 18+ years | Tehran, Iran | [11] |
NCT04944368 | [12] | |||||||
III | IRCT20150303021315N24 | 7 August 2021 | 16,876 | 12,657 | 4,219 | 18–50 years | Tehran, Iran | [3] |
NCT05005559 | [13] |
On 6 October 2021, Iran approved the vaccine for emergency use. [14]
{{
cite journal}}
: Cite journal requires |journal=
(
help)
{{
cite journal}}
: Cite journal requires |journal=
(
help)
{{
cite journal}}
: Cite journal requires |journal=
(
help)